US EditionGRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test
- On May 12, 2025, GRAIL, Inc. And athenahealth revealed a collaboration in Menlo Park, California, to incorporate ordering of GRAIL’s multi-cancer screening blood test into athenahealth’s electronic health record platform.
- This collaboration responds to the ongoing public health crisis of cancer by addressing the need to transform cancer screening before symptoms appear, which improves treatability.
- The integration with athenaCoordinator Core and athenaOne will enable over 160,000 clinicians to order the blood-based Galleri test directly in the EHR, simplifying workflows and increasing patient access to multi-cancer early detection.
- The Galleri test detects DNA fragments shed by cancer cells, acting as a unique “fingerprint” to screen for many deadly cancers, including those without current recommended screening, for adults aged 50 or older at elevated risk.
- As a prescription-only test not approved by the FDA, Galleri should complement routine screenings and requires confirmatory diagnostics for positive results, with results automatically integrated into patient charts to reduce clinician burden.
28 Articles
28 Articles
Montana Standard
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software…
A new blood test designed to detect chemical signs indicating the presence of many different types of cancer
The MCED test opens the door to a future where cancer can be treated before it reaches critical stages Adaptive radiation therapy: how is this important technological breakthrough that allows you to see the tumor in real time?
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test - IT News Direct
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL’s Galleri® multi-cancer early detection (MCED) test into athenaCoordinator C…
Coverage Details
Bias Distribution
- 92% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
